Adlai Nortye (NASDAQ:ANL – Get Free Report) is expected to release its results before the market opens on Wednesday, February 25th. Analysts expect Adlai Nortye to post earnings of ($0.1050) per share and revenue of $10.00 million for the quarter.
Adlai Nortye Stock Performance
Shares of NASDAQ ANL traded up $0.06 during mid-day trading on Friday, reaching $9.92. 293,173 shares of the company traded hands, compared to its average volume of 1,413,138. The company’s fifty day moving average is $4.45 and its two-hundred day moving average is $2.58. Adlai Nortye has a fifty-two week low of $0.88 and a fifty-two week high of $12.09.
Wall Street Analyst Weigh In
ANL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. HC Wainwright upgraded shares of Adlai Nortye from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, February 13th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.00.
About Adlai Nortye
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Featured Articles
- Five stocks we like better than Adlai Nortye
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- Unlocked: Elon Musk’s Next Big IPO
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
